PE-22-28: Research overview, identity, and laboratory handling guide

Spadin-derived 7-residue research peptide studied in vitro for TREK-1 channel binding. Lyophilized, ≥99% HPLC. Research use only. This guide covers identity, published research context, procurement checks, and storage — RUO only, no clinical claims.

What PE-22-28 is in published research

PE-22-28 is a 7-residue analogue derived from the spadin sequence (a 17-residue peptide cleaved from sortilin propeptide). Spadin and its truncated analogues have been studied in vitro for binding to TREK-1 (KCNK2), a two-pore-domain potassium channel of interest in neurochemistry research. Published work has examined receptor binding and downstream signaling in cell-line and ex-vivo neuronal preparations.

PE-22-28 is shipped as a sequence-verified peptide with HPLC purity and MS identity reporting. The short length and exposed N-terminal glutamine require attention to reconstitution buffer pH; labs typically buffer reconstituted material near neutral pH to suppress pyroglutamate formation in storage.

Store lyophilized vials at -20 °C, sealed, away from light. Reconstitute with bacteriostatic water or a near-neutral lab buffer. Aliquot to single-use working volumes before freezing to avoid repeated freeze/thaw cycles.

CoA includes identity (MS), purity (HPLC), net peptide content. Batch records available against the SKU and lot for compliance review.

The material class "Spadin-derived peptide (research)" helps procurement teams group PE-22-28 with related reference peptides during comparative studies.

Sequence and identity

PE-22-28 identity on the catalog: Sequence: H-Gln-Trp-Arg-Glu-Ala-Gly-Glu-OH; Molecular formula: C36H50N10O12; Molecular weight: 830.85 g/mol; Appearance: White lyophilized powder; Purity (HPLC): ≥ 99%; Net peptide: Listed on CoA; Solubility: Soluble in bacteriostatic water. Copy these into receiving and LIMS before reconstitution.

Mechanisms studied in published research

Mechanism-focused research on PE-22-28 is typically conducted in cell lines or biochemical preparations that express the relevant receptor or binding protein for its class.

Design controls that include scrambled-sequence or orthogonal-receptor negative controls when your protocol evaluates PE-22-28 pharmacology in vitro.

Report effect sizes with lot number and CoA reference so results can be reproduced if the same PE-22-28 SKU is reordered later.

Avoid extrapolating in vitro binding or signaling readouts to whole-organism outcomes; RUO materials are not qualified for clinical investigation.

Procurement and identity verification

Request the lot-specific CoA for PE-22-28 at receipt. Verify SKU, variant size if applicable, and identity mass before the lot enters general storage.

Compare HPLC purity to your internal minimum for the peptide family. File chromatogram excerpts when your QMS requires raw data.

Enter net peptide content from the CoA into inventory before calculating molarity for PE-22-28 working stocks.

Attach purchase order, packing list, and CoA in one audit folder per lot.

Storage and reconstitution

Store lyophilized PE-22-28 sealed at -20 °C protected from light unless the CoA states otherwise.

Reconstitute with bacteriostatic water or a buffer validated for your assay pH. Aliquot to limit freeze-thaw.

For oxidation-sensitive sequences in PE-22-28, minimize open-vial time at room temperature during weighing.

See our lyophilized storage guide for institution-scale SOP examples and aliquot labeling conventions.

Comparative reference points

Researchers comparing PE-22-28 with adjacent catalog references often evaluate the following SKUs in parallel plates:

Use matched reconstitution buffers and stock concentrations when running comparative binding or signaling assays.